KY-226 is a
protein tyrosine phosphatase 1B (PTP1B) inhibitor that protects neurons from cerebral ischemic injury.
KY-226 restores Akt (
protein kinase B) phosphorylation and
extracellular signal-regulated kinase (ERK) reduction in transient
middle cerebral artery occlusion (tMCAO) damage. However, the mechanisms underlying the
neuroprotective effects of
KY-226 are unclear. To address this, the effects of
KY-226 on blood-brain barrier (BBB) dysfunction were examined in tMCAO mice.
KY-226 (10 mg/kg, i.p.) was administered to ICR mice 30 min after 2 h of tMCAO. To assess Akt or ERK involvement,
wortmannin (i.c.v.) or
U0126 (i.v.), selective inhibitors of PI3K and ERK, respectively, were administered to mice 30 min before
ischemia. BBB integrity was assessed by
Evans blue leakage 24 h post-reperfusion. The levels of tight junction (TJ)
proteins, ZO-1 and
occludin, were measured by western blotting; ZO-1
mRNA level was measured by RT-PCR. Compared to vehicle,
KY-226 treatment prevented BBB breakdown and reduction in TJ
protein levels.
KY-226 treatment restored ZO-1
mRNA levels post-reperfusion. Pre-administration of
wortmannin or
U0126 blocked the protective effects of
KY-226 on ZO-1
protein and
mRNA reduction in tMCAO mice. In bEnd.3 cells,
lipopolysaccharide treatment reduced
mRNA and
protein levels of ZO-1, an effect rescued by
KY-226 treatment. Further,
KY-226 treatment restored phosphorylation of pAkt (T308) and its downstream target
forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells. Collectively, we demonstrate that
KY-226 protects BBB integrity by restoration of TJ
proteins, an effect partly mediated by Akt/FoxO1 pathway activation. Thus, protection of BBB integrity likely underlies KY-226-induced neuroprotection in tMCAO mice.